Ultragenyx Pharmaceutical Inc. Earnings

Ultragenyx Pharmaceutical Inc.’s revenue jumped 14.65% since last year same period to $159.93Mn in the Q3 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -3.94% fall in its revenue since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit fell -35.12% since last year same period to $-180.41Mn in the Q3 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -56.95% fall in its net profits since last 3-months.

Ultragenyx Pharmaceutical Inc.’s net profit margin fell -17.86% since last year same period to -112.81% in the Q3 2025. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -63.39% fall in its net profit margins since last 3-months.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.21 - a 8.33% jump from last quarter’s estimates.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.21.

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q3 2025. This indicates that the Ultragenyx Pharmaceutical Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.